The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Outcomes and management of patients with R/R myeloma who progress on bispecific antibodies
Tarek H Mouhieddine, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the results of a study investigating the treatment options and outcomes of relapsed/refractory (R/R) patients with multiple myeloma following treatment with bispecific antibodies. Overall, the study found that patients who received another T-cell-directed therapeutic after progressing on a bispecific antibody had deep and durable responses, with progression-free survival (PFS) averaging 28 months. This data suggests that sequential treatment with other T-cell-directed therapeutics such as chimeric antigen receptor (CAR) T-cells or bispecific antibodies is a feasible and promising option for this patient population. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
